Datopotamab Deruxtecan联合帕博利珠单抗±铂类化疗治疗晚期或转移性NSCLC:Ib期TROPION-Lung02试验
TROPION-Lung02是一项Ib期两部分六队列研究,评估Dato-DXd联合帕博利珠单抗±铂类化疗在无驱动基因改变的晚期或转移性NSCLC患者中的安全性和疗效。142例患者接受双药(n=70)或三药(n=72)治疗,其中96例为初治患者。双药和三药组≥3级治疗相关不良事件发生率分别为37.1%和59.7%,未发生治疗相关死亡。初治患者中双药组确认客观缓解率为54.8%,中位缓解持续时间20.1个月,中位无进展生存期11.2个月;三药组分别为55.6%、13.7个月和6.8个月。
要点
- Dato-DXd联合帕博利珠单抗±铂类化疗在晚期NSCLC中显示出可接受的安全性和持久的抗肿瘤活性。
- 初治患者双药组确认ORR为54.8%,中位DOR 20.1个月,中位PFS 11.2个月。
- 初治患者三药组确认ORR为55.6%,中位DOR 13.7个月,中位PFS 6.8个月。
核心结论
- Dato-DXd联合帕博利珠单抗(含或不含铂类化疗)在晚期或转移性NSCLC患者中表现出可接受的安全性和持久的抗肿瘤活性,且在各PD-L1表达水平均观察到肿瘤缓解。
研究设计与样本
- Ib期两部分(剂量递增和扩展)六队列研究TROPION-Lung02,评估Dato-DXd联合帕博利珠单抗±铂类化疗在无驱动基因改变的晚期或转移性NSCLC患者中的安全性和疗效。
- 患者接受Dato-DXd(4或6 mg/kg)联合帕博利珠单抗200 mg单用(双药)或联合铂类化疗(三药;卡铂AUC 5或顺铂75 mg/m2),每3周一次。
- 共142例患者接受双药(n=70)或三药(n=72)治疗,其中96例为初治患者(双药:n=42;三药:n=54)。
- 主要终点为安全性和耐受性,疗效为次要终点;在初治患者亚组中进行了探索性生物标志物分析,采用定量连续评分评估TROP2归一化膜比率。
主要发现
- ≥3级治疗相关不良事件发生率双药组为37.1%,三药组为59.7%;未发生治疗相关死亡。
- 初治患者双药组确认客观缓解率为54.8%,中位缓解持续时间为20.1个月,中位无进展生存期为11.2个月。
- 初治患者三药组确认客观缓解率为55.6%,中位缓解持续时间为13.7个月,中位无进展生存期为6.8个月。
- 两种方案在各PD-L1表达水平均观察到肿瘤缓解。
- 探索性TROP2归一化膜比率生物标志物分析显示,生物标志物阳性患者较阴性患者有生存结局改善的趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The phase Ib two-part (dose escalation and expansion) six-cohort TROPION-Lung02 study evaluated datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum-based chemotherapy (Pt-CT) in patients with advanced or metastatic NSCLC without actionable genomic alterations. METHODS: Patients received Dato-DXd (4 or 6 mg/kg) plus pembrolizumab 200 mg alone (doublet) or with Pt-CT (triplet; carboplatin AUC 5 or cisplatin 75 mg/m2) once every 3 weeks. The primary objective was safety and tolerability; efficacy was a secondary objective. Exploratory biomarker analyses assessing TROP2 normalized membrane ratio by quantitative continuous scoring were performed in the treatment-naive patient subset. RESULTS: In total, 142 patients received doublet (n = 70) or triplet (n = 72) therapy; 96 were treatment-naive (doublet: n = 42; triplet: n = 54). Grade 3 or higher treatment-related adverse events occurred in 37.1% (doublet) and 59.7% (triplet) of patients. No treatment-related deaths occurred. In treatment-naive patients receiving doublet therapy, the confirmed objective response rate was 54.8%, the median duration of response was 20.1 months, and the median progression-free survival was 11.2 months. With triplet therapy, the confirmed objective response rate was 55.6%, the median duration of response was 13.7 months, and the median progression-free survival was 6.8 months. Tumor responses were observed across programmed death-ligand 1 expression levels for both regimens. Exploratory TROP2 normalized membrane ratio biomarker analyses revealed trends toward improved survival outcomes in patients who were biomarker-positive compared with biomarker-negative. CONCLUSION: Dato-DXd plus pembrolizumab therapy (with and without Pt-CT) exhibited appreciable safety and durable antitumor activity across programmed death-ligand 1 expression levels in patients with advanced or metastatic NSCLC. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT04526691.
引用
- Levy B, Paz-Ares L, Lin CC, et al. Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. J Thorac Oncol. 2026. PMID: 41871716. doi:10.1016/j.jtho.2026.103688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。